Sequoia Financial Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.68M | Sell |
2,687
-502
| -16% | -$342K | 0.01% | 706 |
|
|
2026
Q1 | $2.46M | Buy |
3,189
+240
| +8% | +$184K | 0.01% | 537 |
|
|
2025
Q4 | $2.28M | Buy |
2,949
+295
| +11% | +$200K | 0.01% | 533 |
|
|
2025
Q3 | $1.49M | Buy |
2,654
+893
| +51% | +$505K | 0.01% | 616 |
|
|
2025
Q2 | $925K | Buy |
1,761
+146
| +9% | +$81.5K | 0.01% | 710 |
|
|
2025
Q1 | $1.02M | Sell |
1,615
-134
| -8% | -$92.2K | 0.01% | 609 |
|
|
2024
Q4 | $1.25M | Buy |
1,749
+9
| +0.5% | +$7.55K | 0.01% | 517 |
|
|
2024
Q3 | $1.83M | Buy |
1,740
+218
| +14% | +$243K | 0.02% | 395 |
|
|
2024
Q2 | $1.6M | Buy |
1,522
+73
| +5% | +$70.8K | 0.02% | 378 |
|
|
2024
Q1 | $1.39M | Sell |
1,449
-650
| -31% | -$618K | 0.02% | 400 |
|
|
2023
Q4 | $1.84M | Buy |
2,099
+900
| +75% | +$741K | 0.02% | 368 |
|
|
2023
Q3 | $987K | Sell |
1,199
-1
| -0.1% | -$786 | 0.02% | 338 |
|
|
2023
Q2 | $862K | Sell |
1,200
-26
| -2% | -$20K | 0.01% | 375 |
|
|
2023
Q1 | $1.01M | Buy |
1,226
+174
| +17% | +$131K | 0.02% | 313 |
|
|
2022
Q4 | $759K | Buy |
1,052
+668
| +174% | +$493K | 0.02% | 346 |
|
|
2022
Q3 | $265K | Sell |
384
-94
| -20% | -$59.2K | 0.01% | 425 |
|
|
2022
Q2 | $283K | Sell |
478
-17
| -3% | -$11.1K | 0.01% | 454 |
|
|
2022
Q1 | $346K | Buy |
495
+93
| +23% | +$58.8K | 0.01% | 450 |
|
|
2021
Q4 | $254K | Buy |
+402
| New | +$247K | 0.01% | 485 |
|
|
2021
Q1 | – | Sell |
-420
| Closed | -$203K | – | 460 |
|
|
2020
Q4 | $203K | Sell |
420
-37
| -8% | -$20K | 0.01% | 398 |
|
|
2020
Q3 | $256K | Sell |
457
-100
| -18% | -$60.6K | 0.01% | 325 |
|
|
2020
Q2 | $347K | Buy |
557
+38
| +7% | +$21.6K | 0.02% | 271 |
|
|
2020
Q1 | $253K | Buy |
+519
| New | +$214K | 0.02% | 292 |
|
|
2017
Q4 | – | Sell |
-559
| Closed | -$250K | – | 319 |
|
|
2017
Q3 | $250K | Sell |
559
-153
| -21% | -$72.8K | 0.03% | 236 |
|
|
2017
Q2 | $350K | Buy |
712
+12
| +2% | +$5.25K | 0.04% | 188 |
|
|
2017
Q1 | $271K | Hold |
700
| – | – | 0.03% | 218 |
|
|
2016
Q4 | $257K | Buy |
+700
| New | +$266K | 0.04% | 225 |
|
|
2016
Q1 | – | Sell |
-546
| Closed | -$296K | – | 214 |
|
|
2015
Q4 | $296K | Buy |
546
+19
| +4% | +$10.3K | 0.12% | 129 |
|
|
2015
Q3 | $245K | Buy |
527
+10
| +2% | +$5.37K | 0.11% | 140 |
|
|
2015
Q2 | $264K | Buy |
+517
| New | +$252K | 0.11% | 150 |
|
Other funds holding REGN
Sequoia Financial Advisors's REGN Position: Q2 2026 in Review
Sequoia Financial Advisors reduced its Regeneron Pharmaceuticals (REGN) stake by 16% in Q2 2026, selling an estimated $342K and leaving 2,687 shares worth $1.68M. The position accounts for 0.01% of the portfolio, ranked #706.
Sequoia Financial Advisors first reported a position in REGN in Q2 2015 and has held it in 30 quarters since. The position peaked at $2.46M in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Sequoia Financial Advisors held 2,687 shares of Regeneron Pharmaceuticals worth $1.68M as of Q2 2026.
- Sequoia Financial Advisors sold 502 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $342K.
- Regeneron Pharmaceuticals made up 0.01% of Sequoia Financial Advisors's portfolio in Q2 2026, its #706 holding.
- Sequoia Financial Advisors first reported a position in Regeneron Pharmaceuticals in Q2 2015 and has held it in 30 quarters since.
- Sequoia Financial Advisors's Regeneron Pharmaceuticals position peaked at $2.46M in Q1 2026.
- 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Sequoia Financial Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.